HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Complications constitute a major risk factor for mortality in hepatitis B virus-related acute-on-chronic liver failure patients: a multi-national study from the Asia-Pacific region.

AbstractBACKGROUND AND AIM:
Cirrhosis is a controversial determinant of mortality in HBV-related acute-on-chronic liver failure (HBV-ACLF). The present study aimed to explore the effects of cirrhosis and the associated risk factors, especially its complications, on the outcome of HBV-ACLF.
METHODS:
A prospective-retrospective cohort of 985 patients was identified from the APASL-ACLF Research Consortium (AARC) database and the Chinese Study Group. Complications of ACLF (ascites, infection, hepatorenal syndrome, hepatic encephalopathy, upper gastrointestinal bleeding) as well as cirrhosis and the current main prognostic models were measured for their predictive ability for 28- or 90-day mortality.
RESULTS:
A total of 709 patients with HBV-ACLF as defined by the AARC criteria were enrolled. Among these HBV-ACLF patients, the cirrhotic group showed significantly higher mortality and complications than the non-cirrhotic group. A total of 36.1% and 40.1% of patients met the European Association for the Study of Liver (EASL)-Chronic Liver Failure consortium (CLIF-C) criteria in the non-cirrhotic and cirrhotic groups, respectively; these patients had significantly higher rates of mortality and complications than those who did not satisfy the CLIF-C criteria. Furthermore, among patients who did not meet the CLIF-C criteria, the cirrhotic group exhibited higher mortality and complication rates than the non-cirrhotic group, without significant differences in organ failure. The Tongji prognostic predictor model score (TPPMs), which set the number of complications as one of the determinants, showed comparable or superior ability to the Chinese Group on the Study of Severe Hepatitis B-ACLF score (COSSH-ACLFs), APASL-ACLF Research Consortium score (AARC-ACLFs), CLIF-C organ failure score (CLIF-C OFs), CLIF-C-ACLF score (CLIF-C-ACLFs), Model for End-Stage Liver Disease score (MELDs) and MELD-sodium score (MELD-Nas) in HBV-ACLF patients, especially in cirrhotic HBV--ACLF patients. Patients with two (OR 4.70, 1.88) or three (OR 8.27, 2.65) complications had a significantly higher risk of 28- or 90-day mortality, respectively.
CONCLUSION:
The presence of complications is a major risk factor for mortality in HBV-ACLF patients. TPPM possesses high predictive ability in HBV-ACLF patients, especially in cirrhotic HBV-ACLF patients.
AuthorsTao Chen, Zhongyuan Yang, Ashok Kumar Choudhury, Mamun Al Mahtab, Jun Li, Yu Chen, Soek-Siam Tan, Tao Han, Jinhua Hu, Saeed S Hamid, Lee Guan Huei, Hasmik Ghazinian, Yuemin Nan, Yogesh K Chawla, Man-Fung Yuen, Harshad Devarbhavi, Akash Shukla, Zaigham Abbas, Manoj Sahu, A K Dokmeci, Laurentias A Lesmana, Cosmas Rinaldi A Lesmana, Shaojie Xin, Zhongping Duan, Wei Guo, Ke Ma, Zhongwei Zhang, Qiuyu Cheng, Jidong Jia, B C Sharma, Shiv Kumar Sarin, Qin Ning
JournalHepatology international (Hepatol Int) Vol. 13 Issue 6 Pg. 695-705 (Nov 2019) ISSN: 1936-0541 [Electronic] United States
PMID31650510 (Publication Type: Journal Article)
Topics
  • Acute-On-Chronic Liver Failure (epidemiology, etiology, mortality, virology)
  • Adult
  • Ascites (complications)
  • Asia (epidemiology)
  • Cohort Studies
  • Databases, Factual
  • Female
  • Hepatitis B virus
  • Humans
  • Liver Cirrhosis (complications)
  • Male
  • Middle Aged
  • Prognosis
  • Prospective Studies
  • Retrospective Studies
  • Risk Factors
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: